These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12205487)

  • 1. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 2. Pfizer-Pharmacia merger bodes ill for biotech?
    Fletcher L
    Nat Biotechnol; 2002 Sep; 20(9):857-8. PubMed ID: 12205489
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 4. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 6. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 7. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 9. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 10. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomics companies shop around for chemical expertise.
    Fletcher L
    Nat Biotechnol; 2004 Feb; 22(2):137-8. PubMed ID: 14755277
    [No Abstract]   [Full Text] [Related]  

  • 12. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 13. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 14. Let the chips fall where they may.
    Jacobs T
    Nat Biotechnol; 2003 Feb; 21(2):129. PubMed ID: 12560829
    [No Abstract]   [Full Text] [Related]  

  • 15. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 16. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 17. Where have all the investors gone?: the case for consolidation.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 19. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 20. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.